Factors affecting outcome in renal cell carcinoma

被引:7
|
作者
Sun, Maxine [1 ]
Shariat, Shahrokh F. [2 ]
Karakiewicz, Pierre I. [1 ,3 ]
机构
[1] Univ Montreal, Ctr Hlth, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ H2X 3J4, Canada
[2] Weill Cornell Med Ctr, Dept Urol, New York, NY USA
[3] Univ Montreal, Ctr Hlth, Dept Urol, Montreal, PQ H2X 3J4, Canada
关键词
outcome; prognostic factors; renal cell carcinoma; INTEGRATED STAGING SYSTEM; POSTOPERATIVE PROGNOSTIC NOMOGRAM; ENDOTHELIAL GROWTH-FACTOR; CANCER-SPECIFIC SURVIVAL; INTERFERON-ALPHA; PREDICT SURVIVAL; MULTIINSTITUTIONAL VALIDATION; SARCOMATOID DIFFERENTIATION; STRATIFICATION TOOL; SEQUENTIAL THERAPY;
D O I
10.1097/MOU.0b013e32833c7b19
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review To review the latest status on prognostic factors in renal cell carcinoma (RCC). Recent findings Many predictive and prognostic factors can help differentiate between favorable and unfavorable RCC phenotypes. There currently exist several clinical and/or pathological, and biological factors, which have been exclusively tested and used in predictive and prognostic models. Nonetheless, the search for highly informative and reliable factors of disease characteristics and progression continues. Conclusion Over the last decade, an increase occurred in the number of models that can predict the treated natural history of RCC. Many of these novel models and previously developed models are tested in a head-to-head fashion, with the intent of identifying the most accurate and valuable tools for clinical practice. Novel prognostic factors and more upto-date models are urgently needed for patients with metastatic RCC, especially in the era of targeted therapies. This should represent the focus of contemporary prognostic modeling in RCC.
引用
收藏
页码:355 / 360
页数:6
相关论文
共 50 条
  • [21] Clinical and Molecular Prognostic Factors in Renal Cell Carcinoma: What We Know So Far
    Tang, Patricia A.
    Vickers, Michael M.
    Heng, Daniel Y. C.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2011, 25 (04) : 871 - +
  • [22] Prognostic and Predictive Factors for Renal Cell Carcinoma
    Suarez, Cristina
    Campayo, Marc
    Bastus, Roma
    Castillo, Sergi
    Etxanitz, Olatz
    Guix, Marta
    Sala, Nuria
    Gallardo, Enrique
    TARGETED ONCOLOGY, 2018, 13 (03) : 309 - 331
  • [23] Sarcomatoid Renal Cell Carcinoma: Clinical Outcome and Survival After Treatment With Sunitinib
    Kunene, Victoria
    Miscoria, Manuela
    Pirrie, Sarah
    Islam, Mohammad R.
    Afshar, Mehran
    Porfiri, Emilio
    CLINICAL GENITOURINARY CANCER, 2014, 12 (04) : 251 - 255
  • [24] Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma
    Shinohara, Nobuo
    Abe, Takashige
    INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (10) : 888 - 897
  • [25] Factors affecting survival and prognosis in surgically treated patients with spinal metastases arising from renal cell carcinoma
    Lei, Ming
    Miao, Jun
    BMC UROLOGY, 2023, 23 (01)
  • [26] Molecular aspects of renal cell carcinoma: a review
    Koul, Hari
    Huh, Jung-Sik
    Rove, Kyle O.
    Crompton, Luiza
    Koul, Sweaty
    Meacham, Randall B.
    Kim, Fernando J.
    AMERICAN JOURNAL OF CANCER RESEARCH, 2011, 1 (02): : 240 - 254
  • [27] Factors Affecting the Time to Recurrence After Radical Nephrectomy for Localized Renal Cell Carcinoma
    Son, Hee-Seo
    Jeon, Seung Hyun
    Chang, Sung-Goo
    KOREAN JOURNAL OF UROLOGY, 2013, 54 (11) : 744 - 749
  • [28] Renal cell carcinoma management and therapies in 2010
    Albouy, B.
    Goupil, M. Gross
    Escudier, B.
    Massard, C.
    BULLETIN DU CANCER, 2010, 97 : S17 - S28
  • [29] Factors affecting survival and prognosis in surgically treated patients with spinal metastases arising from renal cell carcinoma
    Ming Lei
    Jun Miao
    BMC Urology, 23
  • [30] Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib
    Beuselinck, B.
    Oudard, S.
    Rixe, O.
    Wolter, P.
    Blesius, A.
    Ayllon, J.
    Elaidi, R.
    Schoeffski, P.
    Barrascout, E.
    Morel, A.
    Escudier, B.
    Lang, H.
    Zucman-Rossi, J.
    Medioni, J.
    ANNALS OF ONCOLOGY, 2011, 22 (04) : 794 - 800